We are live on ! Find out more
42.95 USD
+0.47
1.11%
At close Updated Sep 16, 3:49 PM EDT
1 day
1.11%
5 days
2.26%
1 month
0.82%
3 months
15.39%
6 months
4.96%
Year to date
-4.96%
1 year
-5.81%
5 years
-25.2%
10 years
46.64%
 

About: Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).

Employees: 5,500

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 25%
Neutral 65%
Negative 10%
Neutral
Seeking Alpha
3 hours ago
Qiagen N.V. (QGEN) Presents at 2026 Global Healthcare Conference Transcript
Qiagen N.V. (QGEN) Presents at 2026 Global Healthcare Conference Transcript
Qiagen N.V. (QGEN) Presents at 2026 Global Healthcare Conference Transcript
Neutral
Seeking Alpha
1 day ago
Qiagen N.V. (QGEN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Qiagen N.V. (QGEN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Qiagen N.V. (QGEN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Positive
Zacks Investment Research
12 days ago
Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue?
Neutral
PRNewsWire
19 days ago
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challenge PLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (NYSE: QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics since 2025.
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
Neutral
Business Wire
19 days ago
QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction
VENLO, Netherlands & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction across diverse assay workflows. The platform delivers highly concentrated DNA and.
QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction
Neutral
Business Wire
23 days ago
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. Jon Pratt most recently served as President and CEO of Filtration Group, leading the business through the completion of its sale to Parker-Hannifin Corpor.
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
Neutral
Business Wire
1 month ago
QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance. The clearance expands QIAGEN's U.S. syndromic testing portfolio into bloodstream infection diagnostics, the fourth major infectious disease area covered by the QIAstat-Dx platform, which is availa.
QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel
Positive
Zacks Investment Research
1 month ago
Understanding Qiagen (QGEN) Reliance on International Revenue
Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Understanding Qiagen (QGEN) Reliance on International Revenue
Negative
MarketBeat
1 month ago
Qiagen Q2 Earnings Call Highlights
Qiagen NYSE: QGEN reported second-quarter 2026 results above its prior outlook, with net sales of $535 million, unchanged year over year on both a reported and constant-exchange-rate basis. The company had forecast an approximately 2% decline at constant exchange rates.
Qiagen Q2 Earnings Call Highlights
Neutral
Seeking Alpha
1 month ago
Qiagen N.V. (QGEN) Q2 2026 Earnings Call Transcript
Qiagen N.V. (QGEN) Q2 2026 Earnings Call Transcript
Qiagen N.V. (QGEN) Q2 2026 Earnings Call Transcript
Price charts implemented using Lightweight Charts™